Real-world study on dapagliflozin usage in patients with Heart Failure (HF) in Germany

Trial Identifier: D1699R00050
Sponsor: AstraZeneca
NCTID:: NCT06336330
Start Date: April 2024
Primary Completion Date: September 2026
Study Completion Date: September 2026
Condition: Heart, Blood & Circulatory - Other; Congestive Heart Failure

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Germany Berlin, Germany, 12555
Germany Chemnitz, Germany, 09113
Germany Gera, Germany, 07551
Germany Hamburg, Germany, 20095
Germany Ludwigsburg, Germany, 71634
Germany Meiningen, Germany, 98617
Germany Mühldorf, Germany, 84453
Germany Münster, Germany, 48149
Germany Nürnberg, Germany, 90402
Germany Passau, Germany, 94032
Germany Pirna, Germany, 01796
Germany Rostock, Germany, 18059
Germany Schwandorf, Germany, 92421
Germany Siegen, Germany, 57072
Germany Steinfurt, Germany, 48565
Germany Straubing, Germany, 94315
Germany Stuttgart, Germany, 70178